Mesa Laboratories, Inc., also known as MLAB, is a highly specialized international technology company known for delivering innovative solutions and high-quality analytical instruments to a wide range of industries. The company is publicly traded and is listed on the NASDAQ Stock Exchange with the ticker 'MLAB', signifying its strong presence in the financial sector.
Domiciled in the state of Colorado, Mesa Laboratories, Inc. was incorporated in 1982. Since then, it has made a name for itself in four distinct businesses: product integrity, infection control, quality control instruments, and point-of-care testing. These business sections cumulatively cover an extensive array of controlled manufacturing applications and healthcare services.
One of the most significant assets of the Mesa Laboratories, Inc. has been its ability to develop and adapt according to the technological advancements of the respective industry. This adaptability has allowed this company to make significant strides in each of its business segments.
In the area of product integrity, MLAB offers data logging solutions and packaging development services to ensure the successful delivery of critical medicines and vaccines around the globe. Its infection control business provides biological indicators and chemical indicators to ensure sterility assurance in the healthcare industry.
As for quality control instruments, Mesa Laboratories, Inc. has been a leading provider of products and services used in process validation applications. This includes a cross-section of industries such as pharmaceutical, medical device, food and beverage, and dialysis. Lastly, in the realm of point-of-care testing, MLAB provides meters, strips, and solutions that are used in healthcare to measure patients’ glucose and lactate levels.
MESA's reputation as a leader in industrial design and high precision manufacturing is underscored by its commitment to quality and customer satisfaction. Striving to create and maintain strong relationships with its customers, MLAB often offers extensive technical support to businesses and users around the world.
Moreover, Mesa Laboratories Inc. has made substantial investments in research and development. This has not only facilitated the creation of innovative and indispensable products but also helped MLAB to forge avenues for future growth and reach more customers.
In summary, Mesa Laboratories, Inc. stands as a testament to innovation, precision, quality, and reliability. With a robust portfolio and a relentless commitment to excellence, MLAB continues to lead the way in specialized analytical instruments and services, demonstrating the immense potential that resides within highly focused technology companies. This makes Mesa Laboratories, Inc. a critical player across multiple industries and a valuable investment option within the financial sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
_07_03_2026_03_50_21_133108.jpg)
MESA LABORATORIES INC /CO/ Director Tripeny R Tony was granted 1,774 derivative securities on September 9, 2026. This transaction represents 100% of Tripeny R Tony’s total derivative securities holding and is classified as an award or grant. Following this award, Tripeny R Tony holds 1,774 derivative securities in the company.
Mesa Laboratories Director Shannon Hall was granted 1,774 Restricted Stock Units (RSUs) on September 9, 2026, as detailed in a Form 4 filing. These RSUs, which represent a conditional right to one share of common stock each, were granted at a price of $0 and are scheduled to vest on September 9, 2027. Following this transaction, Hall directly owns 1,774 derivative securities in the company.
Mesa Laboratories, Inc. (NASDAQ: MLAB) has released the certified results from its annual shareholder meeting held on September 8, 2026. Shareholders elected all seven nominated directors for one-year terms, ratified Baker Tilly US, LLP as the independent auditor, and approved the non-binding advisory resolution on executive compensation. The company reported a strong turnout with 4,872,692 out of 5,595,869 eligible voting shares represented.
Mesa Laboratories Inc (MLAB) shares recently rallied 4.5%, but GuruFocus' GF Value indicates the stock is currently overvalued at $124.76, exceeding its fair value estimate of $106.27. While MLAB has a strong momentum rank and an above-average GF Score of 76/100, its growth prospects are weaker, and insider selling suggests potential reservations about its current valuation. Investors are advised to exercise caution due to the lack of a margin of safety.